Dermatology

1-15 of 15

• 

  RestartResume

  When Topicals Fail: The New IPC Consensus Every Clinician Should Know

  RestartResume

  When Topicals Fail: The New IPC Consensus Every Clinician Should Know

  CME/CE

  When Topicals Fail: The New IPC Consensus Every Clinician Should Know

  0.25 credits

  • 

    

    Linda Stein Gold, MD

  • 

    

    Bruce Strober, MD, PhD

  0.25 credits

• 

  RestartResume

  Pruritus In PN and AD: Challenge How You Manage Itch

  RestartResume

  Pruritus In PN and AD: Challenge How You Manage Itch

  CME/CE

  Pruritus In PN and AD: Challenge How You Manage Itch

  1.00 credit

  • 

    

    Peter A. Lio, MD

  1.00 credit

• 

  RestartResume

  Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

  RestartResume

  Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

  CME/CE

  Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

  1.50 credits

  • 

    

    Andrew F. Alexis, MD, MPH

  • 

    

    Daniel C. Butler, MD

  • 

    

    Shawn G. Kwatra, MD

  1.50 credits

• 

  RestartResume

  Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management

  RestartResume

  Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management

  CME/CE

  Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management

  1.00 credit

  • 

    

    Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM

  • 

    

    Daniel C. Butler, MD

  • 

    

    Benjamin Ungar, MD

  1.00 credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  1.00 program credit

  • 

    

    Sapna Patel, MD

  • 

    

    John M. Kirkwood, MD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit